NCT04657068 2026-03-18
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
Artios Pharma Ltd
Phase 1/2 Recruiting
Clinical Trials
94 trialsNCT06607185 2026-03-13
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Phase 1 Active not recruiting
NCT05239741 2026-03-10
MK-3475-C66
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT05846867 2026-03-04
A Phase Ib/II Clinical Study on AK112 Combined or Not Combined With AK119 in pMMR/MSS Colorectal Cancer
Akeso
Phase 1/2 Active not recruiting
NCT05838768 2026-02-06
Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency.
Novartis
Phase 1 Active not recruiting
NCT07391566 2026-02-06
LPM6690176 in Combination With Chemotherapy and Bevacizumab in Metastatic Colorectal Cancer Patients With RAS Mutation
Luye Pharma Group Ltd.
Phase 1/2 Not yet recruiting
NCT03798626 2026-01-27
Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers
Novartis
Phase 1 Completed
NCT04640480 2026-01-27
Dose-finding Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SNB-101(SN-38) in Patients With Tumors
SN BioScience
Phase 1 Completed
NCT06792695 2026-01-20
CANTOR
AstraZeneca
Phase 2 Recruiting
NCT06974110 2026-01-16
Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
MOMA Therapeutics
Phase 1 Recruiting
NCT05382442 2025-10-14
A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer
Akeso
Phase 2 Active not recruiting
NCT03184870 2025-10-09
A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1/2 Completed
NCT04008030 2025-10-03
CheckMate 8HW
Bristol-Myers Squibb
Phase 3 Active not recruiting
NCT07134205 2025-08-21
The Study of JMT101 Combined With Irinotecan as a ≥3rd-Line Treatment in Metastatic Colorectal Cancer
Shanghai JMT-Bio Inc.
Phase 3 Not yet recruiting
NCT04607421 2025-08-14
A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer
Pfizer
Phase 3 Active not recruiting
NCT03872947 2025-08-03
A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors
Toray Industries, Inc
Phase 1 Active not recruiting
NCT02611024 2025-07-09
Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors
PharmaMar
Phase 1/2 Completed
NCT05330429 2025-07-01
ELEVATE CRC
Gilead Sciences
Phase 2 Terminated
NCT06963502 2025-05-09
A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid Tumors
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 1 Not yet recruiting
NCT05004350 2025-04-15
NAUTICALCRC
Pierre Fabre Medicament
Phase 2 Completed
NCT04553692 2025-03-28
Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers
IGM Biosciences, Inc.
Phase 1 Terminated
NCT00545545 2025-03-19
Safety/Efficacy Study of Imprime PGG With Cetuximab in Patients With Recurrent/Progressive Colorectal Carcinoma
HiberCell, Inc.
Phase 1/2 Completed
NCT03374254 2024-11-21
KEYNOTE-651
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT03678883 2024-11-07
9-ING-41 in Patients with Advanced Cancers
Actuate Therapeutics Inc.
Phase 2 Active not recruiting
NCT05039944 2024-07-18
SI-B001 as a Single Agent or in Combination With Chemotherapy in the Treatment of Digestive System Malignancies
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2 Terminated
NCT00891930 2024-07-17
Study to Evaluate Mechanisms of Acquired Resistance to Panitumumab
NantBioScience, Inc.
Phase 2 Completed
NCT00838578 2024-04-26
Phase I/II Study of KRN330 Plus Irinotecan in Patients With Metastatic Colorectal Cancer
Kyowa Kirin Co., Ltd.
Phase 1/2 Terminated
NCT02928224 2023-12-21
BEACON CRC
Pfizer
Phase 3 Completed
NCT02753127 2023-11-15
CanStem303C
Sumitomo Pharma America, Inc.
Phase 3 Completed
NCT01133990 2023-11-07
FOLFIRI Alone Versus FOLFIRI Plus Bevacizumab Versus FOLFIRI Plus E7820 as Second-Line Therapy in Patients With Locally Advanced or Metastatic Colorectal Cancer
Eisai Inc.
Phase 1/2 Terminated
NCT06089330 2023-10-18
A Study of JMT101 in Patients With Metastatic Colorectal Cancer
Shanghai JMT-Bio Inc.
Phase 2 Unknown
NCT04627142 2022-04-20
A Study to Test Different Doses of BI 1701963 in Combination With Irinotecan in People With Advanced Bowel Cancer With Kirsten Rat Sarcoma Viral Oncogene Homologue (KRAS) Mutation
Boehringer Ingelheim
Phase 1 Terminated
NCT02641873 2022-04-12
A Study of BBI608 Administrated With FOLFIRI + Bevacizumab in Adult Patients With Metastatic Colorectal Cancer
Sumitomo Pharma Co., Ltd.
Phase 1 Completed
NCT03454620 2022-03-03
A Study to Assess Safety, Efficacy, Immunogenicity, PK of GC1118 With Combination Chemotherapy
GC Biopharma Corp
Phase 1/2 Completed
NCT00856375 2021-07-12
NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal Cancer
Nektar Therapeutics
Phase 2 Completed
NCT01075048 2021-04-08
ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer
Daiichi Sankyo
Phase 1/2 Completed
NCT03368859 2021-02-09
A Study of ABT-165 Plus FOLFIRI vs Bevacizumab Plus FOLFIRI in Subjects With Metastatic Colorectal Cancer Previously Treated With Fluoropyrimidine, Oxaliplatin and Bevacizumab
AbbVie
Phase 2 Terminated
NCT01394939 2021-01-08
Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma
SillaJen, Inc.
Phase 1/2 Completed
NCT00437268 2020-07-21
A Study of Irinotecan Plus Cetuximab With or Without Enzastaurin in Participants With Colorectal Cancer
Eli Lilly and Company
Phase 2 Completed
NCT01803282 2020-06-02
Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors
Gilead Sciences
Phase 1 Completed
NCT00967616 2020-05-04
Study of CS-7017 in Combination With FOLFIRI in Subjects With Metastatic Colorectal Cancer Who Failed First-Line Therapy
Daiichi Sankyo
Phase 2 Completed
NCT01183780 2019-09-25
A Study in Second Line Metastatic Colorectal Cancer
Eli Lilly and Company
Phase 3 Completed
NCT02069704 2019-07-23
Bioequivalence Study Bevacizumab Biosimilar (BEVZ92) Versus Bevacizumab (AVASTIN®) in First-line Treatment mCRC Patients
mAbxience Research S.L.
Phase 1 Completed
NCT01039506 2019-05-29
An Observational Study of CPT-11 Based Regimens and UGT1A1 Genotypes in Metastatic Colorectal Cancer (mCRC)
Daiichi Sankyo
Completed
NCT01479465 2019-04-17
Efficacy and Safety of Simtuzumab (SIM) With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Gilead Sciences
Phase 2 Terminated
NCT01550055 2019-04-10
CRC009
Shanghai Zhangjiang Biotechnology Limited Company
Phase 2/3 Completed
NCT01588990 2019-01-22
ASCENT
Hoffmann-La Roche
Phase 4 Completed
NCT01925274 2019-01-08
A Study Of PF-05212384 Plus Irinotecan Vs Cetuximab Plus Irinotecan In Patients With KRAS And NRAS Wild Type Metastatic Colorectal Cancer
Pfizer
Phase 2 Terminated
NCT00418938 2018-10-17
SPIRITT - Second-Line Panitumumab Irinotecan Treatment Trial
Amgen
Phase 2 Completed
NCT00816777 2018-09-07
PARAGON
Generic Devices Consulting, Inc.
Phase 1/2 Terminated